Ultrasound-guided secondary radiofrequency ablation combined with chemotherapy in gastric cancer with recurrent liver metastasis

Gastric cancer is a kind of common clinical malignant tumors, of which the incidence and mortality accounts for the fourth and second place respectively in the global malignancy. According to the statistics, there are more than 1 million new cases of gastric cancer and about 800,000 deaths worldwide every year (1). In China, its morbidity and mortality rates are ranked second and third in malignant tumors, respectively (2). Because of the atypical clinical symptoms of gastric cancer, most gastric cancer patients have been in the advanced stage when diagnosed. In addition, due to the specificity of anatomical structure and venous return, about 5–14% of patients may have liver metastases (3,4), which is an important cause of death in gastric cancer patients (5), and directly affects patient’s survival and quality of life. Most patients with gastric cancer and liver metastases have lost surgical opportunities, so they are often given palliative care or chemotherapy and Original Article